Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Onchocerca volvulus | 1 | 2020 | 15 | 0.680 |
Why?
|
| Onchocerciasis | 1 | 2020 | 20 | 0.670 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2020 | 85 | 0.640 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 121 | 0.600 |
Why?
|
| Automation, Laboratory | 1 | 2015 | 12 | 0.480 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 53 | 0.470 |
Why?
|
| Occupational Health | 2 | 2005 | 43 | 0.460 |
Why?
|
| Nigeria | 9 | 2012 | 79 | 0.440 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 175 | 0.400 |
Why?
|
| Alcoholic Beverages | 1 | 2010 | 17 | 0.340 |
Why?
|
| Cholinesterases | 2 | 2007 | 10 | 0.330 |
Why?
|
| Organophosphorus Compounds | 2 | 2007 | 23 | 0.330 |
Why?
|
| Hospitals, University | 2 | 2007 | 97 | 0.320 |
Why?
|
| Occupational Diseases | 2 | 2007 | 74 | 0.300 |
Why?
|
| Occupational Exposure | 2 | 2007 | 128 | 0.300 |
Why?
|
| Developing Countries | 3 | 2005 | 271 | 0.300 |
Why?
|
| Follistatin | 1 | 2008 | 35 | 0.300 |
Why?
|
| Activins | 1 | 2008 | 73 | 0.300 |
Why?
|
| Inhibins | 1 | 2008 | 86 | 0.290 |
Why?
|
| Alcoholism | 1 | 2010 | 231 | 0.290 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2513 | 0.280 |
Why?
|
| Aspartic Acid | 1 | 2007 | 73 | 0.280 |
Why?
|
| Alkaline Phosphatase | 1 | 2007 | 98 | 0.280 |
Why?
|
| Alanine Transaminase | 1 | 2007 | 157 | 0.280 |
Why?
|
| Biomarkers | 3 | 2013 | 3091 | 0.270 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 874 | 0.270 |
Why?
|
| Industry | 1 | 2006 | 29 | 0.260 |
Why?
|
| Reproduction | 1 | 2008 | 236 | 0.250 |
Why?
|
| Laboratories, Hospital | 1 | 2005 | 20 | 0.250 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2005 | 51 | 0.250 |
Why?
|
| Antioxidants | 3 | 2013 | 369 | 0.250 |
Why?
|
| Erythrocytes | 1 | 2006 | 219 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 235 | 0.220 |
Why?
|
| Clinical Medicine | 1 | 2004 | 21 | 0.220 |
Why?
|
| Liver Diseases | 1 | 2007 | 367 | 0.220 |
Why?
|
| Laboratories | 1 | 2004 | 81 | 0.210 |
Why?
|
| Safety | 1 | 2004 | 217 | 0.210 |
Why?
|
| Hepatitis C | 1 | 2005 | 365 | 0.190 |
Why?
|
| HIV Infections | 3 | 2010 | 1899 | 0.190 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2005 | 455 | 0.180 |
Why?
|
| Tomography, Emission-Computed | 1 | 2020 | 44 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 854 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 168 | 0.160 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 147 | 0.160 |
Why?
|
| Adult | 10 | 2020 | 29628 | 0.140 |
Why?
|
| Hospitals, Teaching | 3 | 2010 | 104 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2012 | 3300 | 0.130 |
Why?
|
| Biopsy | 1 | 2020 | 1238 | 0.130 |
Why?
|
| Vitamin E | 2 | 2012 | 69 | 0.120 |
Why?
|
| Ascorbic Acid | 2 | 2012 | 78 | 0.120 |
Why?
|
| Quality Control | 1 | 2015 | 121 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 1897 | 0.110 |
Why?
|
| Oxidants | 1 | 2013 | 31 | 0.110 |
Why?
|
| Free Radicals | 1 | 2012 | 37 | 0.100 |
Why?
|
| Humans | 14 | 2020 | 125195 | 0.100 |
Why?
|
| Vitamins | 1 | 2012 | 108 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2013 | 372 | 0.090 |
Why?
|
| Alcoholics | 1 | 2010 | 2 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 2057 | 0.080 |
Why?
|
| Albuminuria | 1 | 2010 | 103 | 0.080 |
Why?
|
| Chagas Disease | 1 | 2013 | 295 | 0.080 |
Why?
|
| Middle Aged | 7 | 2013 | 26928 | 0.080 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 343 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2010 | 1396 | 0.080 |
Why?
|
| Ethanol | 1 | 2010 | 163 | 0.080 |
Why?
|
| Female | 9 | 2020 | 66807 | 0.080 |
Why?
|
| Creatinine | 1 | 2010 | 391 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2893 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2007 | 101 | 0.070 |
Why?
|
| Air Pollutants, Occupational | 1 | 2007 | 18 | 0.070 |
Why?
|
| Infertility | 1 | 2008 | 78 | 0.070 |
Why?
|
| Male | 9 | 2013 | 61526 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2006 | 3465 | 0.070 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 100 | 0.060 |
Why?
|
| Medical Laboratory Personnel | 1 | 2005 | 9 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2005 | 122 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2005 | 160 | 0.060 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2005 | 241 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1271 | 0.050 |
Why?
|
| Adolescent | 3 | 2010 | 19362 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 34234 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2007 | 4817 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2012 | 1131 | 0.040 |
Why?
|
| Time Factors | 1 | 2006 | 6338 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 3730 | 0.030 |
Why?
|
| Pregnancy | 1 | 2005 | 7207 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2012 | 89 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 196 | 0.020 |
Why?
|
| Aged | 3 | 2013 | 19871 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2007 | 16353 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2010 | 308 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 523 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 419 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2010 | 6153 | 0.020 |
Why?
|
| Chemical Industry | 1 | 2007 | 7 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 837 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 507 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2012 | 1375 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2010 | 480 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 1565 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 2458 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8232 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 10315 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 12515 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 14027 | 0.010 |
Why?
|
| Child | 1 | 2010 | 24422 | 0.010 |
Why?
|